IMMUNOVANT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.22 per share for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-03.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-02-03
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $3.38, a 56.50% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $7.77, a 40.73% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-12-31 was $30.65, a 437.72% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $23.26, a 313.14% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.89, a 63.57% decline from fiscal 2021.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $16.17, a 191.88% increase from fiscal 2020.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $5.54, a 100.72% increase from fiscal 2019.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $2.76.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2022-12-31 | $4.22 10-Q · filed 2023-02-03 | |||
| 2022-09-30 | $3.69 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $3.38 10-Q · filed 2022-08-05 | |||
| 2022-03-31 | $5.89 10-K · filed 2022-06-08 | |||
| 2021-12-31 | $6.75 10-Q · filed 2022-02-04 | |||
| 2021-09-30 | $7.21 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $7.77 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $16.17 10-K · filed 2022-06-08 | |||
| 2020-12-31 | $30.65 10-Q · filed 2021-02-16 | $17.81 10-Q · filed 2021-02-16 | ||
| 2020-09-30 | $23.26 10-Q · filed 2020-11-12 | $16.05 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $13.11 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $5.54 10-K · filed 2021-06-01 | |||
| 2019-12-31 | $5.70 10-Q · filed 2021-02-16 | $3.02 10-Q · filed 2021-02-16 | ||
| 2019-09-30 | $5.63 10-Q · filed 2020-11-12 | $5.26 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $5.19 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $2.76 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |